Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
clinical trials
3
×
givosiran
3
×
life sciences
national blog main
aminolevulinic acid
boston
boston top stories
drugs
fda
rna interference
abbvie
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
akouos
allergan
amag pharmaceuticals
amunix
anirvan ghosh
astrazeneca
biogen
biotech
bluerock therapeutics
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cerovene
covid-19
crispr
deals
deerfield management
detroit blog main
detroit top stories
durvalumab
editas medicine
europe blog main
What
alnylam
drug
interference
medicine
pharmaceuticals
rna
rnai
second
seek
speedy
acquisitions
ago
announced
approval
bio
ceo
cleared
collabs
covid
daniel
data
deal
far
fda
gilead
gilead’s
help
indicated
introduce
ipo
market
medicines
month
nasdaq
new
nod
ok
o’day
plans
quick
Language
unset
Current search:
givosiran
×
" clinical trials "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug